Compare · BAX vs INFU
BAX vs INFU
Side-by-side comparison of Baxter International Inc. (BAX) and InfuSystems Holdings Inc. (INFU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BAX and INFU operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BAX is the larger of the two at $42.70B, about 135.7x INFU ($314.7M).
- BAX has been more active in the news (5 items in the past 4 weeks vs 1 for INFU).
- BAX has more recent analyst coverage (25 ratings vs 3 for INFU).
- Company
- Baxter International Inc.
- InfuSystems Holdings Inc.
- Price
- $18.15-1.44%
- $10.31+0.49%
- Market cap
- $42.70B
- $314.7M
- 1M return
- -
- +5.31%
- 1Y return
- -
- +107.86%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 3
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
InfuSystems Holdings Inc.
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) Services. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Latest BAX
- Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
- SEC Form 3 filed by new insider Foster Julie
- SEC Form 3 filed by new insider Wallace Steven P.
- SEC Form 3 filed by new insider Teaff James
- Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
- Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
- Baxter to Host Annual Meeting of Stockholders in Virtual Format
- Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot
- SEC Form DEFA14A filed by Baxter International Inc.
- SEC Form DEF 14A filed by Baxter International Inc.
Latest INFU
- SEC Form DEF 14A filed by InfuSystems Holdings Inc.
- InfuSystems Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- InfuSystem to Participate at 38th Annual ROTH Conference on March 23, 2026
- Executive VP and CFO Steele Barry G bought $18,906 worth of shares (2,064 units at $9.16), increasing direct ownership by 2% to 88,000 units (SEC Form 4)
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by InfuSystems Holdings Inc.
- InfuSystems Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- InfuSystem Announces Financial Results for Fourth Quarter and Full Year 2025
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits